Details

Autor(en) / Beteiligte

• Segman, Yafit
• Ribakovsky, Elena
• Avigdor, Abraham
• Goldhecht, Yair
• Vainstein, Vladimir
• Goldschmidt, Neta
• Harlev, Shimrit
• Horwitz, Netanel
• Gutwein, Odit
• Gurion, Ronit
• Itchaki, Gilad
• Abadi, Uri
• Nemets, Anatoly
• Sofer, Orit
• Zektser, Miri
• Tadmor, Tamar
• Dally, Nagib
• Filanovsky, Kalman
• Leiba, Merav
• Sarid, Nadav
• Benyamini, Noam
• Herishanu, Yair
• Ram, Ron
• Perry, Chava
• Avivi, Irit

Titel

Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience

Ist Teil von

• Leukemia & lymphoma, 2021-01, Vol.62 (1), p.118-124

Ort / Verlag

United States: Taylor & Francis

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The efficacy of polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma outside clinical study are undetermined. This retrospective study examined the efficacy and safety of polatuzumab vedotin administered in real life settings. Forty-seven patients, 31 with de-novo DLBCL and 16 with transformed lymphoma, treated with polatuzumab-based regimen in 14 Israeli centers between June 2018 and November 2019, were included. Median age was 66.1 years (60.4-78.8) and median number of prior lines was 3 (2-7). The overall response rate was 61% (n = 29), including 40% complete responses (n = 19) and 21% (n = 10) partial responses. The median overall survival and progression-free survival were 8.3 months and 5.6 months, respectively. An ECOG PS ≥2 predicted a decreased overall survival (p = 0.045). Primary refractory vs relapsed disease (p = 0.005) and transformed vs de-novo DLBCL (p = 0.039) were associated with shorter PFS (p = 0.027). Our data show that polatuzumab-based regimen is an effective and tolerable treatment in relapsed/refractory DLBCL.